Get the Stockscreener App
1.97
3.43%
-0.07
After Hours:
1.97
Kiora Pharmaceuticals Inc stock is traded at $1.97, with a volume of 30,116.
It is down -3.43% in the last 24 hours and down -6.19% over the past month.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
See More
Previous Close:
$2.04
Open:
$2.11
24h Volume:
30,116
Relative Volume:
0.67
Market Cap:
$7.25M
Revenue:
$20,000
Net Income/Loss:
$-10.84M
P/E Ratio:
-0.7072
EPS:
-2.7857
Net Cash Flow:
$-10.07M
1W Performance:
-2.96%
1M Performance:
-6.19%
6M Performance:
-24.52%
1Y Performance:
-34.11%
1-Day Range:
$1.96
$2.11
1-Week Range:
$1.96
$2.16
52-Week Range:
$1.7645
$4.18
Kiora Pharmaceuticals Inc Stock (KPRX) Company Profile
Name
Kiora Pharmaceuticals Inc
Sector
Industry
Phone
858-224-9600
Address
169 SAXONY RD., ENCINITAS
Compare KPRX vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KPRX
Kiora Pharmaceuticals Inc
|
1.97 | 7.50M | 20,000 | -10.84M | -10.07M | -2.7857 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Kiora Pharmaceuticals Inc Stock (KPRX) Latest News
Kiora Pharmaceuticals Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Kiora Pharmaceuticals reports $10.8M loss for 2025 By Investing.com - Investing.com Canada
Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials - Bitget
Kiora Pharmaceuticals reports $10.8M loss for 2025 - Investing.com
Kiora Pharmaceuticals posts 2025 net loss as expenses rise - TradingView
Kiora Pharmaceuticals 10-K: $0M Revenue, $(10.84)M Net Loss - TradingView
Kiora (NASDAQ: KPRX) posts 2025 loss while funding two active Phase 2 trials - Stock Titan
Retinal disease pipeline at Kiora Pharmaceuticals (NASDAQ: KPRX) - Stock Titan
Two retinal disease trials underway as Kiora says cash lasts into 2027 - Stock Titan
If You Invested $1,000 in KIORA PHARMACEUTICALS INC (KPRX) - Stock Titan
Sectors Review: Is Kiora Pharmaceuticals Inc still a buy after recent gains2026 Trends & AI Driven Stock Reports - baoquankhu1.vn
KPRX Should I Buy - Intellectia AI
Kiora Pharmaceuticals Inc expected to post a loss of 67 cents a shareEarnings Preview - TradingView
Kiora Pharmaceuticals (NASDAQ: KPRX) CFO granted new stock and option awards - Stock Titan
Kiora Pharmaceuticals (KPRX) Upgraded to Strong Buy: Here's What You Should Know - MSN
Kiora Pharmaceuticals (KPRX) CDO uses 238 shares to cover tax withholding - Stock Titan
Kiora Pharmaceuticals (KPRX) CEO disposes 238 shares for taxes - Stock Titan
KPRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Market Fear: Can Kiora Pharmaceuticals Inc keep up with sector leadersRisk Management & Technical Pattern Based Signals - baoquankhu1.vn
KPRXKIORA PHARMACEUTICALS INC Latest Stock News & Market Updates - Stock Titan
Retail Trends: Is Kiora Pharmaceuticals Inc a defensive stockWeekly Trend Recap & Long-Term Growth Stock Strategies - baoquankhu1.vn
What is Kiora Pharmaceuticals Inc. s debt to equity ratioIPO Watch & Community Verified Swing Trade Signals - mfd.ru
SEC EDGAR Submission 0001104659-22-079906 - SEC.gov
Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference - TMX Newsfile
KPRX Technical Analysis & Stock Price Forecast - Intellectia AI
KPRX PE Ratio & Valuation, Is KPRX Overvalued - Intellectia AI
Can Kiora Pharmaceuticals Inc. stock hit record highs againMarket Sentiment Summary & Entry Point Confirmation Alerts - mfd.ru
Weekly Earnings: Whats the profit margin of Kiora Pharmaceuticals IncJuly 2025 Short Interest & Weekly High Return Stock Opportunities - baoquankhu1.vn
Comparing Kiora Pharmaceuticals (NASDAQ:KPRX) and Madrigal Pharmaceuticals (NASDAQ:MDGL) - Defense World
Financial Review: Kiora Pharmaceuticals (NASDAQ:KPRX) & Stevanato Group (NYSE:STVN) - Defense World
Quarterly Earnings: Can MicroSectors Gold Miners 3X Leveraged ETNs due June 29 2040 continue delivering strong returnsTrend Reversal & Target Return Focused Picks - baoquankhu1.vn
Volatility Watch: Is Kiora Pharmaceuticals Inc a defensive stockBond Market & Daily Entry Point Trade Alerts - baoquankhu1.vn
Is Kiora Pharmaceuticals Inc still a buy after recent gains2025 Technical Patterns & Expert Verified Movement Alerts - baoquankhu1.vn
Kiora Pharmaceuticals adds retina specialist to advisory board By Investing.com - Investing.com Canada
Why a leading retinal surgeon is backing new non-steroid eye drugs - Stock Titan
Update Recap: Does Kiora Pharmaceuticals Inc have pricing power2025 EndofYear Setup & Free Community Consensus Stock Picks - baoquankhu1.vn
Trade Recap: Does Kiora Pharmaceuticals Inc have consistent dividend growthMarket Risk Report & Growth-Oriented Investment Plans - baoquankhu1.vn
Can Kiora Pharmaceuticals Inc. stock surprise with earnings upsideDividend Aristocrats List & Outperform With Our Smart Trading Calculator - Bollywood Helpline
Institution Moves: Can ADS TEC Energy PLC Equity Warrant deliver alphaEarnings Growth Summary & Verified Momentum Stock Ideas - baoquankhu1.vn
Fund Flows: Is Kiora Pharmaceuticals Inc stock supported by innovation pipeline2025 Breakouts & Breakdowns & Weekly Top Gainers Alerts - Bộ Nội Vụ
Will Kiora Pharmaceuticals Inc. stock deliver better than expected guidanceMarket Movers & Weekly Stock Performance Updates - Улправда
Will Kiora Pharmaceuticals Inc. (7EY) stock announce a stock splitTrade Ideas & Risk Controlled Daily Plans - Улправда
Why Kiora Pharmaceuticals Inc. (7EY) stock trades below fair valueJuly 2025 Closing Moves & Weekly Market Pulse Updates - Улправда
Is Kiora Pharmaceuticals Inc. stock supported by strong fundamentalsWeekly Trend Recap & Weekly Consistent Profit Watchlists - ulpravda.ru
Kiora Pharmaceuticals, Inc.Common Stock (NQ: KPRX - FinancialContent
Pyxis Oncology (NASDAQ:PYXS) versus Kiora Pharmaceuticals (NASDAQ:KPRX) Head to Head Contrast - Defense World
Kiora Pharmaceuticals (NASDAQ:KPRX) Trading 1.5% Higher – What’s Next? - Defense World
Kiora Pharmaceuticals (KPRX) Stock Analysis Report | Financials & Insights - Benzinga Italia
Aug Intraday: What momentum indicators show for CALX stockPortfolio Gains Summary & Fast Gain Stock Tips - moha.gov.vn
Will Kiora Pharmaceuticals Inc. stock reach all time highs in 2025Weekly Trade Review & Target Return Focused Stock Picks - Улправда
Is Kiora Pharmaceuticals Inc. stock a defensive play in 2025Weekly Stock Analysis & Free Risk Controlled Daily Trade Plans - Улправда
Kiora Pharmaceuticals Inc Stock (KPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):